Targeted treatment and new agents in follicular lymphoma

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 5-11

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Follicular lymphoma; New drugs

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NEW DRUG; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB;

CANCER CHEMOTHERAPY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FOLLICULAR LYMPHOMA; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, FOLLICULAR;

EID: 77955173214     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0608-7     Document Type: Review

References (52)

1. RI Fisher M LeBlanc OW Press DG Maloney JM Unger TP Miller 2005 New treatment options have changed the survival of patients with follicular lymphoma J Clin Oncol 23 8447 8452 10.1200/JCO.2005.03.1674 1:CAS:528:DC%2BD2MXhtlWhtrbJ 16230674
2. W Ozegowski D Krebs 1971 IMET 3393, (-[1-Methyl-5-bis-(β- chloräthyl)-aminobenzimidazolyl-(2)]-butter säurehydrochlorid, ein neues Zytostatikum aus der Reihi der Benzimidazol-Loste Zbl Pharm 110 1013 1019 1:CAS:528:DyaE38Xnt1CmsQ%3D%3D
3. D Strumberg A Harstrick K Doll B Horffmann S Seeber 1996 Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines Anticancer Drugs 7 415 421 10.1097/00001813-199606000-00007 1:CAS:528:DyaK28XkslWru7g%3D 8826610
4. C Schwaenen T Karakas M Schrader 1999 Bendamustine in induction of apoptosis in B-cell chronic lymphocytic leukemia Ann Oncol 10 132 Abstract
5. LM Leoni B Bailey J Reifert, et al. 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309 317 10.1158/1078-0432.CCR-07- 1061 1:CAS:528:DC%2BD1cXoslKk 18172283
6. LM Leoni B Bailey J Reifert 2003 SDX-105 (bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action Blood 102 640a (Abstract 2363)
7. Leoni LM, Bailey B, Niemeyer CC, Kerfoot C, et al. In vivo and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res. 2004;45 (Abstract 1214).
8. KU Chow WD Sommerlad S Boehrer, et al. 2002 Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases Haematologica 87 33 43 1:CAS:528:DC%2BD38XhvF2rsb4%3D 11801463
9. A Heider N Niederle 2001 Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas Anticancer Drugs 12 725 729 10.1097/00001813-200110000-00003 1:CAS:528:DC%2BD3MXosVKltLk%3D 11593053
10. K Bremer 2002 High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas J Cancer Res Clin Oncol 128 603 609 10.1007/s00432-002-0378-6 1:CAS:528:DC%2BD3sXptVyiuw%3D%3D 12458340
11. M Herold A Schulze D Niederwieser, et al. 2006 Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO#19) J Cancer Res Clin Oncol 132 105 112 10.1007/s00432-005-0023-2 1:STN:280:DC%2BD2MnkvFemsg%3D%3D 16088404
12. JW Friedberg P Cohen L Chen, et al. 2008 Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter single-agent study J Clin Oncol 28 204 210 10.1200/JCO.2007.12.5070
13. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: results from a large multicenter study. Cancer. 2010;116:106-114.
14. BD Cheson JW Friedberg BS Kahl RH van der Jagt L Tremmel T Zaks 2009 Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin's lymphoma: a pooled analysis Blood 114 1049 (Abstract #2681)
15. MJ Rummel S Al-Batran SZ Kim, et al. 2005 Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma J Clin Oncol 23 3383 3389 10.1200/JCO.2005.08.100 1:CAS:528:DC%2BD2MXlsVyiu7k%3D 15908650
16. KS Robinson ME Williams RH van der Jagt, et al. 2008 Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: a phase II multicenter study J Clin Oncol 26 4473 4479 10.1200/JCO.2008.17.0001 1:CAS:528:DC%2BD1cXht1ejurzP 18626004
17. MJ Rummel N Niederle G Maschmeyer, et al. 2009 Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood 114 168 169 (Abstract #405)
18. RI Fisher SH Bernstein BS Kahl, et al. 2006 Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 4867 4874 10.1200/JCO.2006.07.9665 17001068
19. OA O'Connor J Wright C Moskowitz, et al. 2005 Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 676 684 10.1200/JCO.2005.02.050 15613699
20. A Goy A Younes P McLaughlin, et al. 2005 Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 667 675 10.1200/JCO.2005.03.108 1:CAS:528:DC%2BD2MXitVKisL0%3D 15613697
21. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2009 (e-pub ahead of print).
22. S de Vos A Goy SR Dakhil, et al. 2009 Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal zone B-cell lymphoma J Clin Oncol 27 5023 5030 10.1200/JCO.2008.17.7980 19770386
23. J Matous J Letzer P Rosen, et al. 2009 Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose-finding results of the VERTICAL study J Clin Oncol 27 446s (Abstract 8550)
24. N Fowler BS Kahl P Rosen, et al. 2009 Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory folicular lymphoma: encouraging activity in the phase 2 VERTICAL study Blood 114 384 385 10.1182/blood-2009-07-234179 (Abstract #933)
25. JW Friedberg JM Vose JL Kelly, et al. 2009 Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin's lymphoma (NHL): a multicenter phase II clinical trial Blood 114 381 (Abstract #924)
26. P Feugier A Van Hoof C Sebban, et al. 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Eetude des Lymphomes de l'Adulte J Clin Oncol 23 4117 4126 10.1200/JCO.2005.09.131 1:CAS:528:DC%2BD2MXmt1elsr0%3D 15867204
27. A Hagenbeek O Gadeberg P Johnson, et al. 2008 First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 111 5486 5495 10.1182/blood-2007-10-117671 1:CAS:528:DC%2BD1cXnsVOkt78%3D 18390837
28. JW Friedberg JM Vose BS Kahl, et al. 2009 A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics Blood 114 1440 1441 (Abstract #3742)
29. G Salles F Morschhauser T Lamy, et al. 2009 Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin's lymphoma (NHL) Blood 114 679 10.1182/blood-2009-02-205989 (Abstract #1704)
30. F Morschhauser JP Leonard L Fayad, et al. 2009 Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results J Clin Oncol 27 3346 3353 10.1200/JCO.2008.19.9117 1:CAS:528: DC%2BD1MXpvFejt7g%3D 19451441
31. Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. Blood. 2009;114 (Abstract 935).
32. JP Leonard M Coleman JC Ketas, et al. 2003 Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma J Clin Oncol 21 3051 3059 10.1200/JCO.2003.01.082 1:CAS:528:DC%2BD2cXpsVWqtLw%3D 12837807
33. JP Leonard M Coleman J Ketas, et al. 2005 Combination antibody therapy with epratuzumab and rituximab in relapsed/refractory non-Hodgkin's lymphoma J Clin Oncol 23 5044 5051 10.1200/JCO.2005.13.821 1:CAS:528:DC%2BD2MXpsFWmtLg%3D 15955901
34. SJ Strauss F Morschhauser J Rech, et al. 2006 Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma J Clin Oncol 24 3880 3886 10.1200/JCO.2006.05.6291 1:CAS:528:DC%2BD28Xps1Sitrs%3D 16864854
35. JP Leonard JW Friedberg A Younes, et al. 2007 A phase I/II study of galiximab (anti-CD80) monoclonal antibody in combination with rituximab for relapsed or refractory follicular lymphoma Ann Oncol 18 1216 1223 10.1093/annonc/mdm114 1:STN:280:DC%2BD2svls1eqtw%3D%3D 17470451
36. MS Czuczman JP Leonard JL Johnson, et al. 2008 FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R] Blood 112 93 (Abstract #233)
37. X Zhao R Lapalombella T Joshi, et al. 2007 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood 110 2569 2577 10.1182/blood-2006-12-062927 1:CAS:528:DC%2BD2sXhtFCnsbjO 17440052
38. PR Baum C Cerveny B Gordon, et al. 2009 Evaluation of the effect of TRU-16, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma J Clin Oncol 27 451s (Abstract 8571)
39. TM) protein in relapsed and refractory CLL: early promising clinical activity. Blood. 2009 (in press).
40. R Bargou E Leo G Zugmaier, et al. 2008 Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974 977 10.1126/science.1158545 1:CAS:528:DC%2BD1cXpslWru70%3D 18703743
41. L Fayad H Patel G Verhoef, et al. 2006 Clinical activity of the immunoconjugate CMC-544 on B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study Blood 108 766a (Abstract 2711)
42. N Dang MR Smith F Offner, et al. 2009 Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or "aggressive" lymphoma Blood 114 242 243
43. AA Chanan-Khan BD Cheson 2008 Lenalidomide for the treatment of B-cell malignancies J Clin Oncol 26 1544 1552 10.1200/JCO.2007.14.5367 1:CAS:528:DC%2BD1cXkslKqsb8%3D 18285605
44. TE Witzig PH Wiernik T Moore, et al. 2009 Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: final results of NHL-001 J Clin Oncol 27 448s 10.1200/JCO.2008.21.1169 (Abstract 8560)
45. N Fowler P McLaughlin FB Hagemeister, et al. 2009 A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma Blood 114 683 10.1182/blood-2009-07-234179 (Abstract #1714)
46. L Chen S Monti P Juszczynski, et al. 2008 SYK-dependent tonic B-cell receptor signalling is a rational treatment target in diffuse large B-cell lymphoma Blood 111 2230 2237 10.1182/blood-2007-07-100115 1:CAS:528: DC%2BD1cXisVeit78%3D 18006696
47. JW Friedberg J Sharman J Sweetenham, et al. 2010 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2578 2585 10.1182/blood-2009-08- 236471 1:CAS:528:DC%2BC3cXksFOhs70%3D 19965662
48. M Ogura T Uchida D Maruyama, et al. 2009 Phase I and pharmacokinetic (PK) study of everolimus (RAD-001) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) Blood 114 682 683 (Abstract #1712)
49. IW Flinn JC Byrd RR Furman, et al. 2009 Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110δ isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies Blood 114 380 10.1182/blood-2008-10-182758 (Abstract #922)
50. BD Cheson JM Vose NL Bartlett, et al. 2009 Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL) J Clin Oncol 27 434s (Abstract 8502)
51. WH Wilson OA O'Connor MS Czuczman, et al. 2009 Phase 1/2a study of ABT-263 in relapsed or refractory lymphoid malignancies Blood 114 682 (Abstract #1711)
52. Younes A, Vose JM, Zelenetz AD, et al. A phase 2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol. 2010 (in press).